Komori
Revision of earnings forecasts2811KAGOME CO.,LTD.Food

Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [IFRS] (Consolidated)

The consolidated full-year earnings forecast for the fiscal year ending December 2026 has been revised. Revenue remains unchanged at ¥310.0 billion, while operating profit has been lowered from ¥23.0 billion to ¥19.5 billion and profit for the period attributable to owners of the parent has been lowered from ¥13.4 billion to ¥10.5 billion. The dividend forecast is unchanged.

Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
-4000
¥ million
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending December 2026 · Full yearPrevious forecast published 2 February 2026
Net Sales310,000→310,000million
0.0%
Operating profit23,000→19,500million
-15.2%
Profit attributable to owners of the parent13,400→10,500million
-21.6%
Net income per share147.47→116.04
-21.3%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

The Company expects the worsening situation in the Middle East to have an approximately ¥2.8 billion impact on business profit, and packaging-related expenses, raw material costs and energy costs are expected to rise. Sales of seeds and other products by United Genetics Holdings LLC to the Middle East are also expected to decline. In addition, for certain products in the beverage category of the domestic processed foods business, the recovery in sales volume following the February price revision has been below expectations.

Previous-period resultsRevenue: ¥294,264 million; business profit: ¥22,366 million; operating profit: ¥22,307 million; profit for the period attributable to owners of the parent: ¥14,800 million; basic earnings per share: ¥161.42
Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net Sales¥310,000 million → ¥310,000 million
Operating profit¥23,000 million → ¥19,500 million(-15.2%)
Profit attributable to owners of the parent¥13,400 million → ¥10,500 million(-21.6%)
Net income per share¥147.47 → ¥116.04(-21.3%)
Fiscal Period CoveredFiscal year ending December 2026
Period CoveredFull year
Publication date of previous forecast2 February 2026
Previous-period resultsRevenue: ¥294,264 million; business profit: ¥22,366 million; operating profit: ¥22,307 million; profit for the period attributable to owners of the parent: ¥14,800 million; basic earnings per share: ¥161.42
Reason for the revisionThe Company expects the worsening situation in the Middle East to have an approximately ¥2.8 billion impact on business profit, and packaging-related expenses, raw material costs and energy costs are expected to rise. Sales of seeds and other products by United Genetics Holdings LLC to the Middle East are also expected to decline. In addition, for certain products in the beverage category of the domestic processed foods business, the recovery in sales volume following the February price revision has been below expectations.
Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated
Items this document does not state (2)
Ordinary incomeDetails and amount of extraordinary loss

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company expects the worsening situation in the Middle East to have an approximately ¥2.8 billion impact on business profit, as well as increases in packaging-related expenses, raw material costs and energy costs, and a decline in seed sales to the Middle East. In addition, for certain domestic beverage products, the recovery in sales volume following the February price revision has been below expectations.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [IFRS] (Consolidated) | KAGOME CO.,LTD. (2811) timely disclosure | Komori